The Orexin System: Sleep, Wakefulness, and Psychiatry
One neuropeptide switch, two opposite drug strategies — how blocking or restoring orexin treats insomnia, narcolepsy, and depression with insomnia
Few discoveries have reorganized a clinical field as cleanly as orexin did for sleep medicine. Identified in 1998, orexin (also called hypocretin) is a hypothalamic neuropeptide that acts as the brain's master switch for wakefulness — and the realization that narcolepsy is essentially an orexin-deficiency disease reframed both how we understand sleep and how we drug it. What makes orexin such a satisfying teaching subject is its symmetry: if too little orexin causes pathological sleepiness, then blocking orexin should treat insomnia, and replacing it should treat narcolepsy. Both halves of that prediction have now produced approved or soon-to-be-approved medicines. This chapter builds the story from the neurobiology up, aimed to be read start to finish by a trainee and used as a mechanism reference by a clinician who prescribes sleep and wake drugs.
The wakefulness switch
Deep in the lateral hypothalamus sits a small population of neurons that produce orexin. Despite their small numbers, these neurons project widely — to the brainstem and basal forebrain arousal centers that use histamine, norepinephrine, serotonin, dopamine, and acetylcholine. Orexin's job is to stabilize the awake state: it holds the arousal system on and keeps the brain from slipping prematurely into sleep, and especially from entering REM sleep at the wrong times.
Sleep scientists describe the brain's sleep–wake control as a "flip-flop switch," a circuit that wants to sit firmly in either the awake or the asleep state and to transition quickly between them rather than dwelling in a groggy in-between. Orexin is the finger on that switch, biasing it toward wakefulness. Remove orexin and the switch becomes unstable: patients fall asleep unpredictably, and the boundaries between wakefulness, sleep, and REM break down. That is precisely the clinical picture of narcolepsy.
Two receptors, two therapeutic doors
Orexin signals through two G-protein-coupled receptors, OX1R and OX2R. OX2R is the more important for maintaining wakefulness and suppressing REM/cataplexy. This distinction matters pharmacologically: a drug can block both receptors (a "dual" antagonist) or selectively engage one. As we will see, the sleep drugs mostly block both, while the newest wake drugs selectively stimulate OX2R.
Narcolepsy: the disease that revealed the system
Narcolepsy type 1 is caused by the autoimmune-mediated loss of orexin-producing neurons. Without orexin's stabilizing influence, patients experience overwhelming daytime sleepiness, fragmented nighttime sleep, and — the near-pathognomonic feature — cataplexy, sudden losses of muscle tone triggered by emotion, which represents REM-sleep muscle atonia intruding into wakefulness. The tight link between low orexin and this syndrome is what told the field, definitively, that orexin was the wakefulness signal. For decades we could only treat narcolepsy's symptoms with stimulants and REM-suppressing antidepressants. The obvious dream was to replace the missing orexin itself — a dream now being realized.
ClinicalBlocking orexin: the DORAs for insomnia
The first therapeutic application ran in the opposite direction — toward sleep. If orexin keeps you awake, an orexin-receptor antagonist should let you sleep. This produced the dual orexin receptor antagonists (DORAs), a genuinely new class of hypnotic that works by reducing wakefulness drive rather than by broadly sedating the brain the way benzodiazepines and "Z-drugs" do through GABA.
- Suvorexant (Belsomra) Approved — the first DORA.
- Lemborexant (Dayvigo) Approved — relatively OX2R-preferring; robust for both sleep onset and maintenance.
- Daridorexant (Quviviq) Approved — designed with a shorter half-life to improve sleep while limiting next-morning grogginess.
The conceptual advantage of the DORAs is that they facilitate sleep while largely preserving normal sleep architecture — they do not suppress deep or REM sleep the way older hypnotics can — and they carry a lower risk of the dependence, tolerance, and cognitive/motor impairment associated with benzodiazepine-receptor agonists. A newer agent, vornorexant Late pipeline, is advancing as the next entry in the class.
Restoring orexin: the agonists for narcolepsy
The most exciting recent development is the arrival of the other half of the symmetry: drugs that stimulate the orexin receptor to replace what narcolepsy destroys. The lead agent is oveporexton (TAK-861) Late pipeline, a selective OX2R agonist. Rather than propping up wakefulness indirectly with a stimulant, it addresses the root cause — the missing orexin signal.
Late pipeline Oveporexton (TAK-861): Phase 3 success
In the pivotal Phase 3 FirstLight and RadiantLight trials in narcolepsy type 1, oveporexton met all primary and secondary endpoints. It restored wakefulness — with a majority of participants reaching normative-range wakefulness on objective measures — reduced cataplexy, and improved cognition, with roughly 70% of treated participants reporting no significant cognitive difficulty versus about 15% on placebo. An FDA decision is anticipated in the second half of 2026. Additional OX2R agonists are following in development, and the class is being explored in narcolepsy type 2 and idiopathic hypersomnia.
This is a landmark not just for narcolepsy but as a proof of concept: it is possible to pharmacologically restore a deficient neuropeptide signal and reverse the clinical syndrome it causes. It also completes the intellectual arc — block orexin for insomnia, restore orexin for narcolepsy — that makes this system such a clear demonstration of mechanism-driven drug design.
Clinical — the psychiatric crossoverSeltorexant: treating depression through the sleep switch
The place where the orexin system most directly enters psychiatry is seltorexant Late pipeline, a selective OX2R antagonist developed specifically as an adjunctive treatment for major depressive disorder with insomnia symptoms. The rationale is elegant: rather than adding a sedating antipsychotic to an antidepressant, target the OX2R to improve the sleep disturbance that is both a symptom and a driver of depression.
The results require an honest reading. In the pivotal Phase 3 MDD3005 trial, seltorexant was compared head-to-head against quetiapine XR (a common but side-effect-laden adjunct). Seltorexant produced a numerically higher response rate at 26 weeks (about 57% versus 53%), but this did not reach statistical significance on the primary endpoint. Both drugs improved depressive symptoms substantially. Where seltorexant clearly distinguished itself was tolerability: markedly fewer side effects and better study completion than quetiapine XR. So the honest headline is not "seltorexant is more effective" but "seltorexant may match a standard adjunct with a far better tolerability profile" — a meaningful clinical proposition, but not the efficacy win the mechanism promised.
ClinicalThe gray-market footnote: sleep peptides
No discussion of orexin and sleep is complete without noting what is being sold around it. Delta sleep-inducing peptide (DSIP / emideltide) Gray-market is a decades-old peptide marketed for sleep, and it appeared on the FDA's July 2026 compounding advisory docket. Unlike the orexin drugs, it has scant modern controlled evidence for efficacy. The contrast is the whole lesson of this chapter in miniature: on one side, a rigorously trialed OX2R agonist that reverses narcolepsy; on the other, a compounded sleep peptide riding a regulatory loophole with little data behind it. When a patient asks about a "sleep peptide," this is the distinction to draw — and the peptides-and-biologics chapter covers the compounding decision in full.
SynthesisOne system, at a glance
| Agent | Action on orexin | Indication | Status |
|---|---|---|---|
| Suvorexant (Belsomra) | DORA (blocks) | Insomnia | Approved |
| Lemborexant (Dayvigo) | DORA (blocks) | Insomnia | Approved |
| Daridorexant (Quviviq) | DORA (blocks) | Insomnia | Approved |
| Vornorexant | DORA (blocks) | Insomnia | Late pipeline |
| Seltorexant | Selective OX2R antagonist | MDD with insomnia (adjunct) | Phase 3 — primary missed |
| Oveporexton (TAK-861) | Selective OX2R agonist | Narcolepsy type 1 | Phase 3 positive; FDA decision 2H 2026 |
| DSIP / emideltide | Not an orexin drug | Marketed for sleep | Gray-market |
Conclusion
The orexin system is the cleanest example in modern psychopharmacology of biology dictating therapeutics. A single neuropeptide stabilizes wakefulness; too little of it produces narcolepsy, and manipulating its receptors in either direction produces useful medicines. Blocking orexin gave us the DORAs — hypnotics that improve insomnia while sparing sleep architecture and sidestepping benzodiazepine liabilities, a real advance for the many psychiatric patients whose insomnia is entangled with their illness. Restoring orexin has now given us oveporexton, a Phase 3 success that reverses narcolepsy at its root and stands as a proof of concept for replacing a deficient neuropeptide. And in seltorexant, the system reaches directly into depression treatment, with a Phase 3 story that is honest about the difference between a tolerability advantage and an efficacy win. For the clinician, orexin is both a set of prescribable tools and a model of how understanding a mechanism precisely lets you drug it in whichever direction the patient needs. The companion chapters place this system in the wider pipeline and in the peptide-and-biologic landscape it belongs to.